mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
复制标题
DOI：
--
复制
发表时间：
2010-12
期刊：
影响因子：
--
通讯作者：
H. Gerullis;T. Ecke;Christoph Eimer;Heuck Cj;T. Otto
中科院分区：
文献类型：
--
作者：
H. Gerullis;T. Ecke;Christoph Eimer;Heuck Cj;T. Otto
坦西莫司是哺乳动物雷帕霉素靶点的有效抑制剂，包括细胞周期、血管生成和增殖，并已被证明对晚期肾细胞癌（RCC）的治疗有益。替西莫司被正式批准用于高风险、未经治疗的mRCC患者的一线治疗。本文就替西莫司治疗晚期肾细胞癌的药理特点、毒性和耐受性等方面的临床作用进行综述。它特别讨论了生活质量问题作为mRCC患者姑息治疗的重要结果参数，并对temsirolimus可能的未来联合/测序策略的当前临床发展进行了展望。
The potent inhibitor of the mammalian target of rapamycin, temsirolimus, comprises for cell cycle, angiogenesis and proliferation and has proven beneficial in the treatment of advanced renal cell carcinoma (RCC). Temsirolimus is officially approved for first line therapy in high risk previously untreated mRCC patients. This review summarizes the current clinical role of temsirolimus in the treatment of advanced renal cell carcinoma with regard to pharmacological features, toxicity and tolerability. It particularily discusses quality of life issues as important outcome parameters in palliative treatment of patients with mRCC and gives an outlook on current clinical developments regarding possible future combining/ sequencing strategies of temsirolimus.